WNT3A and glioma: Dysregulation of the Wnt canonical pathway leading to beta-catenin activation has been detected in glioma patients with overexpression of WNT3a [5] and epigenetic-driven downregulation of inhibitors like SFRP1, Dkk1 or Wif1 [36, 37].